What's new? Log in Free sign up

CG Oncology, Inc. Common stock (CGON)

Company Profile

Company profile

Ticker

CGON

Exchange

Website

CEO

Mr. Arthur Kuan

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Silexion Therapeutics • Amgen • Gilead Sciences • Biogen • Qiagen • Sterling Check • Bio-Techne • Moderna • bluebird bio • Acorda Therapeutics ...

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

SafeGuard Healthcare, LLC ...

IRS number

371611499

CGON stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Submission of Matters to a Vote of Security Holders

Quarterly report

13 May 25

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

Regulation FD Disclosure

Annual report to shareholders

Additional proxy soliciting materials

Definitive proxy

Automatic shelf registration

28 Mar 25

CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

Latest ownership filings

View all

Brian Guan-Chyun Liu

Victor Edward Tong Jr

TCG Crossover GP I, LLC

Financial summary

Financial statements Chart CGON financial data

Quarter (USD)	Mar 25	Dec 24	Sep 24	Jun 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	41.47 mm	41.47 mm	41.47 mm	41.47 mm	41.47 mm	41.47 mm
Cash burn (monthly)	71.87 mm	3.00 mm	14.07 mm	11.20 mm	9.76 mm	6.83 mm
Cash used (since last report)	186.05 mm	7.77 mm	36.42 mm	29.00 mm	25.26 mm	17.69 mm
Cash remaining	-144.58 mm	33.71 mm	5.05 mm	12.48 mm	16.21 mm	23.79 mm
Runway (months of cash)	-2.0	11.2	0.4	1.1	1.7	3.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

CGON institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	146	127	+15.0%
Opened positions	37	25	+48.0%
Closed positions	18	16	+12.5%
Increased positions	60	60	–
Reduced positions	28	19	+47.4%

13F shares	Current	Prev Q	Change
Total value	1.86 tn	1.94 tn	-3.7%
Total shares	87.48 mm	74.43 mm	+17.5%
Total puts	34.50 k	50.50 k	-31.7%
Total calls	198.70 k	53.10 k	+274.2%
Total put/call ratio	0.2	1.0	-81.7%

Largest owners	Shares	Value	Change
Decheng Capital	6.37 mm	$182.74 bn	+16.3%
Vanguard	5.86 mm	$168.10 bn	+15.3%
Decheng Capital Global Life Sciences Fund IV	5.32 mm	$160.28 mm	+7.2%
BlackRock	4.06 mm	$116.47 bn	+13.7%
TCG Crossover Management	3.67 mm	$105.26 bn	0.0%
Unique Diamond Investments	3.59 mm	$108.27 mm	-27.3%
TCG Crossover GP I	3.57 mm	$158.52 mm	0.0%
Kissei Pharmaceutical	3.54 mm	$131.11 mm	0.0%
Braidwell	3.28 mm	$94.17 bn	+3.5%
Longitude Capital Partners IV	3.19 mm	$118.05 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
FMR	2.43 mm	+2.29 mm	+1571.4%
Foresite Capital Management VI	2.22 mm	+2.22 mm	NEW
Marshall Wace	1.46 mm	+1.45 mm	+18836.0%
Wellington Management	1.91 mm	+1.40 mm	+274.4%
Ra Capital Management	0.00	-1.40 mm	EXIT
Unique Diamond Investments	3.59 mm	-1.35 mm	-27.3%
Acorn Capital Advisors	1.13 mm	+1.13 mm	NEW
BVF	0.00	-994.60 k	EXIT
UBS UBS	1.01 mm	+927.36 k	+1071.7%
Decheng Capital	6.37 mm	+892.86 k	+16.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CGON insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
5 Jun 25	Hong Fang Song	Director Stock Option Common Stock	Grant	Acquire A	No	No	26.63	24,165	643.51 k	24,165
5 Jun 25	James Mulay	Director Stock Option Common Stock	Grant	Acquire A	No	No	26.63	24,165	643.51 k	24,165
5 Jun 25	Victor Edward Tong Jr	Director Stock Option Common Stock	Grant	Dispose A	No	No	26.63	24,165	643.51 k	24,165
5 Jun 25	Susan E Graf	Director Stock Option Common Stock	Grant	Acquire A	No	No	26.63	24,165	643.51 k	24,165
5 Jun 25	Leonard E Post	Director Stock Option Common Stock	Grant	Acquire A	No	No	26.63	24,165	643.51 k	24,165

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Morgan Stanley Maintains Overweight on CG Oncology, Raises Price Target to $56

Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $52 to $56.

Morgan Stanley Maintains Overweight on CG Oncology, Lowers Price Target to $52

Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and lowers the price target from $55 to $52.

CG Oncology Q1 EPS $(0.45) Misses $(0.41) Estimate, Sales $52.00K Miss $212.75K Estimate

CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.41) by 9.76 percent. This is a 25 percent decrease over losses of $(0.36) per share from the

Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?

JP Morgan Initiates Coverage On CG Oncology with Overweight Rating, Announces Price Target of $41

Press releases

From Benzinga Pro

CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

IRVINE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing

SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

- Award recipients Honored at the American Urological Association's 2025 Annual Meeting - - Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients

CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.